Drug Type Small molecule drug |
Synonyms D Serine |
Target |
Action agonists |
Mechanism NMDA receptor agonists(Glutamate [NMDA] receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC3H7NO3 |
InChIKeyMTCFGRXMJLQNBG-UWTATZPHSA-N |
CAS Registry312-84-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Schizophrenia | Phase 3 | - | - | |
Schizophrenia | Phase 3 | - | - | |
Parkinson Disease | Phase 2 | - | - | |
Parkinson Disease | Phase 2 | - | - | |
Stress Disorders, Post-Traumatic | Phase 2 | - | - | |
Stress Disorders, Post-Traumatic | Phase 2 | - | - |
Phase 2 | 16 | (D-serine) | gkuohoetpi(pfbbbxgtyb) = pabxnbcssn ehxtdzkgmg (kgvxkajauk, 9.3) View more | - | 02 Aug 2017 | ||
Placebo (Placebo) | gkuohoetpi(pfbbbxgtyb) = zkqktdvdcw ehxtdzkgmg (kgvxkajauk, 10.3) View more | ||||||
Phase 4 | 39 | (D-serine (Glutamate Agonist)) | jphvxdcdkl(ilkbhknmha) = adxlvpyohi emjvvxpina (wuzhzyumlb, 8.1) View more | - | 01 Jul 2014 | ||
(Riluzole (Glutamate Antagonist)) | jphvxdcdkl(ilkbhknmha) = eteolxzbse emjvvxpina (wuzhzyumlb, 7.2) View more |